2025
Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulsePatient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis
Sanacora G, Barnett B, Hu B, Goes F, Mathew S, Murrough J, Reti I, Wilkinson S, Anand A. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. Psychiatry Research 2025, 347: 116411. PMID: 40049091, DOI: 10.1016/j.psychres.2025.116411.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyResistant depressionTreatment adherenceResponse to ketamineECT-treated patientsTreatment outcome measuresInfluence treatment adherencePatient-Centered Outcomes Research InstituteAssociated with greater likelihoodKetamine treatmentIV ketamineAdverse eventsEffect of patients' preferencesPreference effectsPatient preferencesRandomized patients to treatmentKetamineRate of adverse eventsTreatment responseGreater likelihoodPatients to treatmentPhase completionTreatment preferencesDepressionTuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary
D'Ottavi M, Godfrey-Faussett P, Merle C, Sofonea M, Laureillard D, Vickerman P, Molès J, Altice F, Van de Perre P, Stone J, Nagot N. Tuberculosis and people who use drugs: why focus on this overlooked population is important and why adapted interventions are necessary. The Lancet Global Health 2025, 13: e593-e598. PMID: 39862874, DOI: 10.1016/s2214-109x(24)00481-9.Peer-Reviewed Original ResearchConceptsReduce health inequalitiesCommunity-based approachActive case findingNational Tuberculosis ProgrammeHealth inequalitiesTargeted interventionsTuberculosis interventionsCase findingTreatment adherenceGeneral populationTuberculosis ProgrammeMarginalised populationsHIV fieldInterventionPrevalence of tuberculosisTuberculosis burdenPopulation levelTuberculosis transmissionHigher incidencePeoplePopulationAdherenceHIVPrevalenceLinkage
2024
An updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. An updated comparative analysis of needs and role of patient navigation among early phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 20: 237-237. DOI: 10.1200/op.2024.20.10_suppl.237.Peer-Reviewed Original ResearchSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationClinical trialsPatient navigationFinancial toxicitySDoHSymptom burdenCare systemImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsPhase clinical trialsTrial participantsLevel of acceptanceLonger visitsVulnerable populationsNon-participantsTreatment adherenceScreening visitEvaluating differences in receipt of survivorship care plan among cancer survivors with and without disabilities
Sarkar S, Zaidi M, Raziani Y, Poghosyan H. Evaluating differences in receipt of survivorship care plan among cancer survivors with and without disabilities. Supportive Care In Cancer 2024, 32: 637. PMID: 39235704, DOI: 10.1007/s00520-024-08796-6.Peer-Reviewed Original ResearchConceptsSurvivorship care plan receiptSurvivorship care plansDisability countCancer survivorsCare planningReceipt of survivorship care plansMethodsWe analyzed cross-sectional dataBehavioral Risk Factor Surveillance SystemFollow-up care instructionsRisk Factor Surveillance SystemSelf-reported cancer historyTreatment adherenceSelf-care difficultiesMultinomial multivariable logistic regressionIndependent living difficultiesPromote treatment adherenceMultivariate logistic regressionCancer survivorshipCross-sectional dataTreatment summarySelf-careCancer historyNo disabilityLiving difficultiesResultsThe samplePatient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities
Neparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare 2024, 12: 1587. PMID: 39201146, PMCID: PMC11354118, DOI: 10.3390/healthcare12161587.Peer-Reviewed Original ResearchDisease journeyHealth care providersImprove patient supportCare providersPatient prioritiesPatient advocatesPatient perspectiveMedical appointmentsMultiple myelomaPatient supportMultiple barriersInformed treatment decisionsPrioritized needsMultidisciplinary teamTreatment adherenceDisease burdenFocus group researchComprehensive supportImprove outcomesSocial workersTreatment decisionsInsurance optionsMixing methodBurdenSupport640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1Water-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisDermatitisPrescription productsTrialsTreatment adherence and clinical outcomes amongst in people with drug-susceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa: a cluster randomized trial
Charalambous S, Maraba N, Jennings L, Rabothata I, Cogill D, Mukora R, Hippner P, Naidoo P, Xaba N, Mchunu L, Velen K, Orrell C, Fielding K. Treatment adherence and clinical outcomes amongst in people with drug-susceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa: a cluster randomized trial. EClinicalMedicine 2024, 75: 102745. PMID: 39170937, PMCID: PMC11338121, DOI: 10.1016/j.eclinm.2024.102745.Peer-Reviewed Original ResearchEvidence of improved adherenceTreatment adherencePrimary health clinicsCluster randomised trialCluster randomized trialStandard of careDifferentiated care approachesPoor treatment adherenceMedical monitoringCare approachHealth clinicsAdherence reportsLower treatment completionCluster designDrug-susceptible tuberculosisPrimary outcomeRandomised trialsDrug-sensitive tuberculosisAdherenceTreatment completionCareParticipantsSouth AfricaRandomized trialsFollow-upCOVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration
Soyer E, McGinnis K, Justice A, Hsieh E, Rodriguez-Barradas M, Williams E, Park L. COVID-19 Breakthrough Infection after Vaccination and Substance Use Disorders: A Longitudinal Cohort of People with and without HIV Receiving Care in the United States Veterans Health Administration. AIDS And Behavior 2024, 28: 3605-3614. PMID: 39046612, DOI: 10.1007/s10461-024-04449-1.Peer-Reviewed Original ResearchHIV statusSubstance use disordersBreakthrough infectionRisk of breakthroughAssociated with increased riskCOVID-19 breakthrough infectionsSARS-CoV-2Association of substance useSARS-CoV-2 infectionHIV treatment adherenceCD4 countHIV progressionSubstance useUnited States Veterans Health AdministrationHazard ratioIncreased riskPWHCD4PWoHHIVUse disorderVaccinated personsCohort of peopleTreatment adherenceLongitudinal cohortUnit costs and cost-effectiveness of a device to improve TB treatment adherence in China
Sweeney S, Fielding K, Liu X, Thompson J, Dong H, Jiang S, Zhao Y, Huan S, Vassall A. Unit costs and cost-effectiveness of a device to improve TB treatment adherence in China. IJTLD OPEN 2024, 1: 299-305. PMID: 39035432, PMCID: PMC11257087, DOI: 10.5588/ijtldopen.23.0451.Peer-Reviewed Original ResearchIntervention cost-effectivenessHealth facility levelIncremental cost-effectiveness ratioProbabilistic sensitivity analysesTB treatment adherenceCluster-randomised superiority trialImprove treatment outcomesIncremental cost-effectivenessCost-effectiveness ratioIncremental costCost-effectiveDiscount rateUnit cost dataTreatment adherenceFacility levelLack of evidenceTreatment outcomesImprove adherenceDigital adherence technologiesEnhance patient managementScenario analysisSocietal perspectiveSuperiority trialStandard of careAdherence technologiesEnhancing Adherence with Children and Families in the Treatment of Avoidant/Restrictive Food Intake Disorder
Salvatore Farkas L, Ashurova M, Hochman A, Dave S, Shimshoni Y. Enhancing Adherence with Children and Families in the Treatment of Avoidant/Restrictive Food Intake Disorder. 2024, 83-94. DOI: 10.1007/978-3-031-58141-0_6.Peer-Reviewed Original ResearchAvoidant/restrictive food intake disorderTreatment of avoidant/restrictive food intake disorderFood intake disorderEnhance adherenceHealth care literacyImprove treatment adherenceCare literacyMotivational interviewingIncrease patientsFamily complianceOptimal careDistorted body imageMedical educationTreatment adherenceBulimia nervosaAnorexia nervosaTreatment planningBody imageAdherenceNervosaTreatmentDisordersCaregiversCareCommitment practicesEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost hoc analysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDDA comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center.
Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 42: e23127-e23127. DOI: 10.1200/jco.2024.42.16_suppl.e23127.Peer-Reviewed Original ResearchSDoH barriersEarly phase clinical trialsCancer clinical trial participationSocial drivers of healthDrivers of healthHealth care systemClinical trial participationPatient navigationNavigation interventionClinical trialsFinancial toxicityIdentified barriersCare systemSDoHImprove participationNeeds assessmentDiagnosis to treatmentDescriptive characteristicsTrial participantsLevel of acceptanceVulnerable populationsNon-participantsPhase clinical trialsTreatment adherenceScreening visitThe Causes and Consequences of Stigma Among Individuals Involved in the Criminal Legal System: A Systematic Review
Moore K, Phillips S, Kromash R, Siebert S, Roberts W, Peltier M, Smith M, Verplaetse T, Marotta P, Burke C, Allison G, McKee S. The Causes and Consequences of Stigma Among Individuals Involved in the Criminal Legal System: A Systematic Review. Stigma And Health 2024, 9: 224-235. PMID: 39381322, PMCID: PMC11456775, DOI: 10.1037/sah0000483.Peer-Reviewed Original Research504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.Peer-Reviewed Original ResearchPhase 3 trialLocal tolerancePatient treatment adherenceAdverse eventsPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasAtopic dermatitisRoflumilast creamDay 1Seborrheic dermatitisWater-based creamRoflumilastInvestigational productPatientsInvestigator-PsoriasisPrescription productsTrialsClinicInvestigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis
Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.Peer-Reviewed Original ResearchPhase 3 trialLocal toleranceAdverse eventsPatient treatment adherencePatients discontinued due to adverse eventsAtopic dermatitisSeborrheic dermatitisPenetration enhancersRoflumilast-treated patientsRate of adverse eventsTreatment adherencePatient-rated assessmentsApplication siteTopical medicationsIntertriginous areasRoflumilast creamDay 1RoflumilastWater-based creamInvestigator-Investigational productPatientsPsoriasisDermatitisPrescription products
2023
Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments.
Sen S. Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments. The American Journal Of Managed Care 2023, 29: s180-s186. PMID: 37677742, DOI: 10.37765/ajmc.2023.89415.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyReduced ejection fractionHeart failureEjection fractionEconomic burdenManagement of HFrEFPresence of comorbiditiesEmergency department visitsVentricular ejection fractionDisease-modifying therapiesPoor treatment adherenceHealth care systemDepartment visitsMedical therapyPatient factorsComorbid conditionsMedication costsTreatment adherenceOptimal treatmentOutpatient carePreventable hospitalizationsIndividual patientsHigh riskTarget dosesMedical costsmHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study
Cossio A, Bautista-Gomez M, Alexander N, Del Castillo A, del Mar Castro M, Castaño-Grajales P, Gutiérrez-Poloche Y, Zuluaga L, Vargas-Bernal L, Navarro A, Saravia N. mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study. American Journal Of Tropical Medicine And Hygiene 2023, 109: 778-790. PMID: 37640290, PMCID: PMC10551068, DOI: 10.4269/ajtmh.22-0805.Peer-Reviewed Original ResearchConceptsCommunity health leadersProportion of patientsAdverse drug reactionsCutaneous leishmaniasisDrug reactionsTherapeutic responseHealth workersCutaneous leishmaniasis patientsInitiation of treatmentAnti-leishmanial treatmentStandard of careGlobal health problemMobile health strategiesEffectiveness of treatmentPublic health needsLeishmaniasis patientsCare groupTreatment adherenceHealth strategiesMHealth interventionsPatientsHealth problemsHealth needsMHealth strategiesCase identificationInternet-Delivered, Therapist-Assisted Treatment for Anxiety and Depression in Patients with Cardiovascular Disease: Evidence-Base and Challenges
Pedersen S, Skovbakke S, Skov O, Carlbring P, Burg M, Habibović M, Ahm R. Internet-Delivered, Therapist-Assisted Treatment for Anxiety and Depression in Patients with Cardiovascular Disease: Evidence-Base and Challenges. Current Cardiology Reports 2023, 25: 443-453. PMID: 37119450, DOI: 10.1007/s11886-023-01867-w.Peer-Reviewed Original ResearchConceptsInternet-based psychological interventionsFace-to-face therapyTherapist-assisted treatmentInterventions targeting anxietyInternet-based therapyCardiovascular diseaseComorbid anxietyPsychological interventionsDevelopment of interventionsAssessment of fidelityHealth care costsAnxietyDepressionTreatment adherenceHealth literacyFace-to-faceHealth careCare costsPatient reportsEvidence-basedClinical outcomesReviewThis reviewHealthPatientsInterventionLearning from community-based HIV prevention to inform control and mitigation of the COVID-19 pandemic
Abrams J, Rutledge J, Opara I. Learning from community-based HIV prevention to inform control and mitigation of the COVID-19 pandemic. Preventive Medicine 2023, 169: 107445. PMID: 36750159, PMCID: PMC9899509, DOI: 10.1016/j.ypmed.2023.107445.Peer-Reviewed Original ResearchConceptsFuture viral pandemicsHIV preventionCommunity-based HIV preventionHuman immunodeficiency virus (HIV) preventionCOVID-19 pandemicViral pandemicHIV-negative individualsCommunity-based prevention strategiesHIV testing behaviorsPublic health initiativesCommunity-based effortsTertiary prevention effortsHealth communication strategiesMode of transmissionCommunity-based strategiesHIV screeningHIV testingTreatment initiationTreatment adherenceCurrent COVID-19 pandemicPrevention strategiesNegative individualsHealth initiativesCondom useCurrent COVID-19
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply